Brokerage Research Reports share price target

Focus on process efficiency to get visible from FY22E onwards While there is uncertainty on a recovery that is solely dependent on launch of vaccine, the company has initiated major steps to bring down costs and come out stronger and more efficient once normalcy resumes. EIH is now focusing more on process efficiency measures on a permanent basis like back-office automation, using AI, paperless processing, focus on solar panel to bring down power costs, expertise driven services in finance, data management etc. Considering this, we expect over 7-8% reduction in total...

has seen large sales return as climatic conditions was adverse to weed germination. There has been low-to-normal pest infestation in Paddy, Cotton and Maize, till date. White fly attack in North on Cotton crop led to multifold growth in sales of Diafenthiuron + Pyriproxyfen combination molecule (Key pulses, horticulture and Cotton have driven growth for the industry. Channel inventory is low and collections have been the best in over a decade. Despite normal demand industry is likely to see decent ~15% growth due to massive gain in market share from local/unorganised players. Our channel checks...

has seen large sales return as climatic conditions was adverse to weed germination. There has been low-to-normal pest infestation in Paddy, Cotton and Maize, till date. White fly attack in North on Cotton crop led to multifold growth in sales of Diafenthiuron + Pyriproxyfen combination molecule (Key pulses, horticulture and Cotton have driven growth for the industry. Channel inventory is low and collections have been the best in over a decade. Despite normal demand industry is likely to see decent ~15% growth due to massive gain in market share from local/unorganised players. Our channel checks...

IRCTC's performance was marred by COVID-19 during 1QFY21 with EBITDA/PAT loss of Rs439mn (PLe of Rs522mn)/Rs246mn (PLe of Rs308mn) respectively. With gradual relaxation in lockdown restrictions (80 additional...

Mid/Small caps could witness a shift of Rs120bn and Rs220bn to Mid/small caps till the date of compliance in Jan2021 Nifty increased by 9.5% upto Jan 18 while...

Mid/Small caps could witness a shift of Rs120bn and Rs220bn to Mid/small caps till the date of compliance in Jan2021 Nifty increased by 9.5% upto Jan 18 while...

With 3.9% YoY decline in IPM in this fiscal already, India formulations focused companies may need to revise their growth estimates downward for FY21E. While Indian economy heads towards gradual re-opening, IPM growth hasn't witnessed much revival even with no restriction imposed on the industry. Apart from few therapies like Cardiac and Anti-Diabetic, rest have been on a declining trend or lacked consistent growth. India formulations sales declined (YoY) for majority stakeholders. We expect similar trend could follow in 2QFY21E as well as key players have reported decline in sales in first five...

With 3.9% YoY decline in IPM in this fiscal already, India formulations focused companies may need to revise their growth estimates downward for FY21E. While Indian economy heads towards gradual re-opening, IPM growth hasn't witnessed much revival even with no restriction imposed on the industry. Apart from few therapies like Cardiac and Anti-Diabetic, rest have been on a declining trend or lacked consistent growth. India formulations sales declined (YoY) for majority stakeholders. We expect similar trend could follow in 2QFY21E as well as key players have reported decline in sales in first five...

Key takeaways from our recent interaction with the management of Greenpanel Industries (GREENP).